Cleerly ISCHEMIA vs SENSICARDIAC

SENSICARDIAC offers a highly intuitive user experience with its 'guided auscultation process' and real-time analysis, directly integrating with electronic stethoscopes at the point of care. Its browser-based platform (via Telesensi) further simplifies deployment and interaction. Cleerly ISCHEMIA, while providing interactive web-based reports, is an add-on to existing CCTA workflows, which may involve more complex data transfer and review steps.

Cleerly ISCHEMIA provides a comprehensive and quantitative assessment of coronary artery disease, including non-invasive FFR estimation and detailed plaque characterization, validated against invasive gold standards with demonstrated impact on treatment decisions and prognostic value for MACE. While SENSICARDIAC offers highly accurate murmur detection and classification, Cleerly's solution addresses a more complex and critical diagnostic challenge in cardiovascular care with deeper physiological insights. Its ability to provide detailed, actionable data from a single non-invasive scan represents a significant advancement.

SENSICARDIAC, through the Telesensi platform, offers transparent subscription pricing ranging from $25 to $100 per user per month, making its cost structure predictable and potentially more accessible. Cleerly ISCHEMIA's pricing is not publicly available and 'varies by provider,' making direct cost-value comparison difficult, despite being billable under a Category I CPT code. The clear, publicly stated pricing model of SENSICARDIAC offers a more straightforward value proposition.

Both tools demonstrate strong enterprise readiness with FDA clearance, HIPAA compliance, and BAA availability. Cleerly ISCHEMIA's explicit integration with PowerScribe via API and secure data transfer via Cleerly Proxy (VPN or virtual appliance) indicates a robust and mature strategy for deep integration into existing radiology and cardiology enterprise workflows. SENSICARDIAC also offers cloud-based management and APIs, but Cleerly's specific integration within a complex imaging ecosystem gives it a slight advantage in demonstrating readiness for large-scale, secure deployment within established healthcare IT environments.

Cleerly ISCHEMIA's capability to non-invasively estimate fractional flow reserve (FFR) and provide detailed coronary plaque characterization from CCTA scans represents a significant innovation, addressing a diagnostic challenge that traditionally required invasive procedures. This offers a more profound technological and clinical advancement in understanding and managing complex coronary artery disease. SENSICARDIAC's real-time AI-powered heart murmur detection via electronic stethoscopes is also innovative for point-of-care and telehealth, but Cleerly's solution tackles a more intricate physiological modeling problem with broader implications for personalized treatment planning.

Cleerly provides a comprehensive array of support resources, including dedicated client support, extensive publications, webinars, imaging protocols, patient education, FAQs, and detailed billing and coverage guidelines. SENSICARDIAC (via Telesensi) offers onboarding training, demo sessions, and white papers, along with a user manual. Cleerly's broader and more transparent public documentation, particularly for a complex diagnostic tool, suggests a more robust and accessible support ecosystem.